Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate

Vibeke Strand, Stanley Cohen, Michael Schiff, Arthur Weaver, Roy Fleischmann, Grant Cannon, Robert Fox, Larry Moreland, Nancy Olsen, Dan Furst, Jacques Caldwell, Jeffrey Kaine, John Sharp, Frank Hurley, Iris Loew-Friedrich

Research output: Contribution to journalArticle

670 Citations (Scopus)

Abstract

Context: Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA). Objective: To compare the efficacy and safety of leflunomide treatment with placebo and methotrexate treatment in patients with active RA. Design: Randomized, double-blind, placebo, and active-controlled 12-month study. Setting: Forty-seven university and private rheumatology practices in the United States and Canada. Patients: Diagnosis of RA by the American College of Rheumatology (ACR) criteria for duration of 6 months or longer and no previous methotrexate treatment. Intervention: Leflunomide treatment (20 mg/d), placebo, or methotrexate treatment (7.5-15 mg/wk). Main Outcome Measures: American College of Rheumatology success rate (completed 52 weeks of treatment and met the ACR ≥20% response criteria), disease progression as assessed by x-ray films, and improvement in function and health-related quality of life using the intent-to-treat population. Results: The 482 patients studied were predominantly women (mean age, 54 years; mean disease duration, 6.7 years) for whom a mean of 0.8 disease- modifying anti- rheumatic drugs had failed. The ACR response and success rates for patients receiving leflunomide treatment (52% and 41%, respectively) and methotrexate treatment (46% and 35%, respectively) were significantly higher than those for patients receiving placebo (26% and 19%, respectively) (P<.001), and they were statistically equivalent, with mean time to initial response at 8.4 weeks for patients receiving leflunomide vs 9.5 weeks for patients receiving methotrexate therapy. X-ray analyses demonstrated less disease progression with leflunomide (P≤.001) and methotrexate (P = .02) therapy than with placebo. Leflunomide and methotrexate treatment improved measures of physical function and health- related quality of life significantly more than placebo (P<.001 and P<.05, respectively). Common adverse events for patients receiving leflunomide treatment included gastrointestinal complaints, skin rash, and reversible alopecia. Asymptomatic transaminase elevations resulted in treatment discontinuations for 7.1% of patients receiving leflunomide therapy, 1.7% of patients receiving placebo, and 3.3% of patients receiving methotrexate therapy. Conclusions: Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to those with methotrexate treatment. Both active treatments improved signs and symptoms of active RA, delayed disease progression as demonstrated by x-ray films, and improved function and health-related quality of life.

Original languageEnglish (US)
Pages (from-to)2542-2550
Number of pages9
JournalArchives of Internal Medicine
Volume159
Issue number21
DOIs
StatePublished - Nov 22 1999

Fingerprint

leflunomide
Methotrexate
Rheumatoid Arthritis
Placebos
Therapeutics
Rheumatology
Disease Progression
Quality of Life
X-Rays

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., ... Loew-Friedrich, I. (1999). Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Archives of Internal Medicine, 159(21), 2542-2550. https://doi.org/10.1001/archinte.159.21.2542
Strand, Vibeke ; Cohen, Stanley ; Schiff, Michael ; Weaver, Arthur ; Fleischmann, Roy ; Cannon, Grant ; Fox, Robert ; Moreland, Larry ; Olsen, Nancy ; Furst, Dan ; Caldwell, Jacques ; Kaine, Jeffrey ; Sharp, John ; Hurley, Frank ; Loew-Friedrich, Iris. / Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. In: Archives of Internal Medicine. 1999 ; Vol. 159, No. 21. pp. 2542-2550.
@article{224b7eef20dc45a0aefdb934f4b06ac1,
title = "Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate",
abstract = "Context: Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA). Objective: To compare the efficacy and safety of leflunomide treatment with placebo and methotrexate treatment in patients with active RA. Design: Randomized, double-blind, placebo, and active-controlled 12-month study. Setting: Forty-seven university and private rheumatology practices in the United States and Canada. Patients: Diagnosis of RA by the American College of Rheumatology (ACR) criteria for duration of 6 months or longer and no previous methotrexate treatment. Intervention: Leflunomide treatment (20 mg/d), placebo, or methotrexate treatment (7.5-15 mg/wk). Main Outcome Measures: American College of Rheumatology success rate (completed 52 weeks of treatment and met the ACR ≥20{\%} response criteria), disease progression as assessed by x-ray films, and improvement in function and health-related quality of life using the intent-to-treat population. Results: The 482 patients studied were predominantly women (mean age, 54 years; mean disease duration, 6.7 years) for whom a mean of 0.8 disease- modifying anti- rheumatic drugs had failed. The ACR response and success rates for patients receiving leflunomide treatment (52{\%} and 41{\%}, respectively) and methotrexate treatment (46{\%} and 35{\%}, respectively) were significantly higher than those for patients receiving placebo (26{\%} and 19{\%}, respectively) (P<.001), and they were statistically equivalent, with mean time to initial response at 8.4 weeks for patients receiving leflunomide vs 9.5 weeks for patients receiving methotrexate therapy. X-ray analyses demonstrated less disease progression with leflunomide (P≤.001) and methotrexate (P = .02) therapy than with placebo. Leflunomide and methotrexate treatment improved measures of physical function and health- related quality of life significantly more than placebo (P<.001 and P<.05, respectively). Common adverse events for patients receiving leflunomide treatment included gastrointestinal complaints, skin rash, and reversible alopecia. Asymptomatic transaminase elevations resulted in treatment discontinuations for 7.1{\%} of patients receiving leflunomide therapy, 1.7{\%} of patients receiving placebo, and 3.3{\%} of patients receiving methotrexate therapy. Conclusions: Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to those with methotrexate treatment. Both active treatments improved signs and symptoms of active RA, delayed disease progression as demonstrated by x-ray films, and improved function and health-related quality of life.",
author = "Vibeke Strand and Stanley Cohen and Michael Schiff and Arthur Weaver and Roy Fleischmann and Grant Cannon and Robert Fox and Larry Moreland and Nancy Olsen and Dan Furst and Jacques Caldwell and Jeffrey Kaine and John Sharp and Frank Hurley and Iris Loew-Friedrich",
year = "1999",
month = "11",
day = "22",
doi = "10.1001/archinte.159.21.2542",
language = "English (US)",
volume = "159",
pages = "2542--2550",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "21",

}

Strand, V, Cohen, S, Schiff, M, Weaver, A, Fleischmann, R, Cannon, G, Fox, R, Moreland, L, Olsen, N, Furst, D, Caldwell, J, Kaine, J, Sharp, J, Hurley, F & Loew-Friedrich, I 1999, 'Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate', Archives of Internal Medicine, vol. 159, no. 21, pp. 2542-2550. https://doi.org/10.1001/archinte.159.21.2542

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. / Strand, Vibeke; Cohen, Stanley; Schiff, Michael; Weaver, Arthur; Fleischmann, Roy; Cannon, Grant; Fox, Robert; Moreland, Larry; Olsen, Nancy; Furst, Dan; Caldwell, Jacques; Kaine, Jeffrey; Sharp, John; Hurley, Frank; Loew-Friedrich, Iris.

In: Archives of Internal Medicine, Vol. 159, No. 21, 22.11.1999, p. 2542-2550.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate

AU - Strand, Vibeke

AU - Cohen, Stanley

AU - Schiff, Michael

AU - Weaver, Arthur

AU - Fleischmann, Roy

AU - Cannon, Grant

AU - Fox, Robert

AU - Moreland, Larry

AU - Olsen, Nancy

AU - Furst, Dan

AU - Caldwell, Jacques

AU - Kaine, Jeffrey

AU - Sharp, John

AU - Hurley, Frank

AU - Loew-Friedrich, Iris

PY - 1999/11/22

Y1 - 1999/11/22

N2 - Context: Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA). Objective: To compare the efficacy and safety of leflunomide treatment with placebo and methotrexate treatment in patients with active RA. Design: Randomized, double-blind, placebo, and active-controlled 12-month study. Setting: Forty-seven university and private rheumatology practices in the United States and Canada. Patients: Diagnosis of RA by the American College of Rheumatology (ACR) criteria for duration of 6 months or longer and no previous methotrexate treatment. Intervention: Leflunomide treatment (20 mg/d), placebo, or methotrexate treatment (7.5-15 mg/wk). Main Outcome Measures: American College of Rheumatology success rate (completed 52 weeks of treatment and met the ACR ≥20% response criteria), disease progression as assessed by x-ray films, and improvement in function and health-related quality of life using the intent-to-treat population. Results: The 482 patients studied were predominantly women (mean age, 54 years; mean disease duration, 6.7 years) for whom a mean of 0.8 disease- modifying anti- rheumatic drugs had failed. The ACR response and success rates for patients receiving leflunomide treatment (52% and 41%, respectively) and methotrexate treatment (46% and 35%, respectively) were significantly higher than those for patients receiving placebo (26% and 19%, respectively) (P<.001), and they were statistically equivalent, with mean time to initial response at 8.4 weeks for patients receiving leflunomide vs 9.5 weeks for patients receiving methotrexate therapy. X-ray analyses demonstrated less disease progression with leflunomide (P≤.001) and methotrexate (P = .02) therapy than with placebo. Leflunomide and methotrexate treatment improved measures of physical function and health- related quality of life significantly more than placebo (P<.001 and P<.05, respectively). Common adverse events for patients receiving leflunomide treatment included gastrointestinal complaints, skin rash, and reversible alopecia. Asymptomatic transaminase elevations resulted in treatment discontinuations for 7.1% of patients receiving leflunomide therapy, 1.7% of patients receiving placebo, and 3.3% of patients receiving methotrexate therapy. Conclusions: Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to those with methotrexate treatment. Both active treatments improved signs and symptoms of active RA, delayed disease progression as demonstrated by x-ray films, and improved function and health-related quality of life.

AB - Context: Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA). Objective: To compare the efficacy and safety of leflunomide treatment with placebo and methotrexate treatment in patients with active RA. Design: Randomized, double-blind, placebo, and active-controlled 12-month study. Setting: Forty-seven university and private rheumatology practices in the United States and Canada. Patients: Diagnosis of RA by the American College of Rheumatology (ACR) criteria for duration of 6 months or longer and no previous methotrexate treatment. Intervention: Leflunomide treatment (20 mg/d), placebo, or methotrexate treatment (7.5-15 mg/wk). Main Outcome Measures: American College of Rheumatology success rate (completed 52 weeks of treatment and met the ACR ≥20% response criteria), disease progression as assessed by x-ray films, and improvement in function and health-related quality of life using the intent-to-treat population. Results: The 482 patients studied were predominantly women (mean age, 54 years; mean disease duration, 6.7 years) for whom a mean of 0.8 disease- modifying anti- rheumatic drugs had failed. The ACR response and success rates for patients receiving leflunomide treatment (52% and 41%, respectively) and methotrexate treatment (46% and 35%, respectively) were significantly higher than those for patients receiving placebo (26% and 19%, respectively) (P<.001), and they were statistically equivalent, with mean time to initial response at 8.4 weeks for patients receiving leflunomide vs 9.5 weeks for patients receiving methotrexate therapy. X-ray analyses demonstrated less disease progression with leflunomide (P≤.001) and methotrexate (P = .02) therapy than with placebo. Leflunomide and methotrexate treatment improved measures of physical function and health- related quality of life significantly more than placebo (P<.001 and P<.05, respectively). Common adverse events for patients receiving leflunomide treatment included gastrointestinal complaints, skin rash, and reversible alopecia. Asymptomatic transaminase elevations resulted in treatment discontinuations for 7.1% of patients receiving leflunomide therapy, 1.7% of patients receiving placebo, and 3.3% of patients receiving methotrexate therapy. Conclusions: Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to those with methotrexate treatment. Both active treatments improved signs and symptoms of active RA, delayed disease progression as demonstrated by x-ray films, and improved function and health-related quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0033596065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033596065&partnerID=8YFLogxK

U2 - 10.1001/archinte.159.21.2542

DO - 10.1001/archinte.159.21.2542

M3 - Article

C2 - 10573044

AN - SCOPUS:0033596065

VL - 159

SP - 2542

EP - 2550

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 21

ER -